ImmunoGen, Inc. (IMU.F)

4.0715 -0.0620 (-1.50%) As of 08:02AM CEST. Market open.

ImmunoGen, Inc.

830 Winter Street
Waltham, MA 02451-1477
United States
781 895 0600
https://www.immunogen.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 106

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Mark Joseph Enyedy	Pres, CEO & Director	1.24M	N/A	1964
Ms. Susan Altschuller Ph.D.	Sr. VP & CFO	537.53k	N/A	1983
Dr. Anna Berkenblit M.D., MM.Sc	Sr. VP & Chief Medical Officer	647.28k	N/A	1970
Ms. Stacy A. Coen	Sr. VP & Chief Bus. Officer	547.66k	N/A	1971
Ms. Kristen Harrington-Smith	Sr. VP & Chief Commercial Officer	562.52k	N/A	1973
Ms. Renee Lentini	VP of Fin. & Principal Accounting Officer	N/A	N/A	1978
Ms. Courtney O'Konek	Sr. Director of Corp. Communications & Investor Relations	N/A	N/A	N/A
Mr. Joseph J. Kenny	VP, Acting Gen. Counsel, Intellectual Property & Sec.	N/A	N/A	N/A
Ms. Audrey Bergan	Sr. VP & Chief HR Officer	N/A	N/A	N/A
Dr. Theresa G. Wingrove	Sr. VP of Regulatory Affairs & Quality	N/A	N/A	1958

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Corporate Governance

ImmunoGen, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.